Indian stock benchmarks fell on Friday, logging their fifth straight weekly loss - the longest losing streak in two years - ...

Weiss (Tex.) wide receiver Tre Moore sat down with Rivals' Sam Spiegelman this week to discuss his recruitment. The ...

With US markets touching all-time highs, foreign markets being relatively cheaper, and global investors being over-indexed to ...

The tricky part is that it isn't always easy to find companies you can buy and hold. The corporate landscape is ruthlessly ...

The 2025 edition of the Blue-Chip Ratio was released this week, providing an annual snapshot at the teams that have been ...

Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

On July 24, Emily Roland, Manulife John Hancock Investments co-chief investment strategist, appeared on CNBC’s ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.

Here's a closer look at five potential breakout candidates among former Midwest four- and five-stars in the Big Ten.

These S&P/ASX 200 Index (ASX: XJO) blue-chip shares are worth holding if you already own them but are too expensive for new ...